tailieunhanh - Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: An ancillary study derived from a randomized clinical trial

We report here a correlation analysis conducted along with a phase II trial assessing bevacizumab in combination with weekly paclitaxel. | Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab An ancillary study derived from a randomized clinical trial

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN